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Type II cellTTF-1 is an important transcription factor in lung development and lung disease and is essential for lung cell
differentiation, speciﬁcally surfactant protein (Sftp) expression. The molecular mechanisms that drive the
expression and transcriptional control of TTF-1 are not fully understood. In the fetal lung, ErbB4 functions
as a transcriptional co-factor and regulates the timely onset of fetal Sftp expression. We speculate that
ErbB4 is an upstream regulator of TTF-1 and regulates Sftpb expression via this pathway in alveolar type II
cells. Neuregulin-induced ErbB4 and TTF-1 signaling interactions were studied by co-immunoprecipitation
and confocal microscopy. Overexpression of ErbB4 and TTF-1 was analyzed in its effect on cell viability,
Sftpb expression, TTF-1 expression, and Sftpb and TTF-1 promoter activity. The effect of ErbB4 deletion and
ErbB4 nuclear translocation on TTF-1 expression was studied in primary fetal type II epithelial cells, isolated
from transgenic HER4heart(−/−) mice. ErbB4 ligand neuregulin induces ErbB4 and TTF-1 co-precipitation and
nuclear colocalization. Combined ErbB4 and TTF-1 overexpression inhibits cell viability, while promoting
Sftpb expression more than single overexpression of each protein. NRG stimulates TTF-1 expression in
ErbB4-overexpressing epithelial cells, while this effect is absent in ErbB4-depleted cells. In primary fetal
type II cells, ErbB4 nuclear translocation is critical for its regulation of TTF-1-induced Sftpb upregulation.
TTF-1 overexpression did not overcome this important requirement. We conclude that ErbB4 is a critical up-
stream regulator of TTF-1 in type II epithelial cells and that this interaction is important for Sftpb regulation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Thyroid transcription factor (TTF)-1, also known as Nkx2-1, is a
homeodomain containing transcription factor and a member of the
NK2 homeobox 1 (Nkx2) family, which activates the expression of
genes in the thyroid, lung, and brain [1]. TTF-1 is a transcriptional reg-
ulator that plays a key role in embryonic lung development and lung
cell differentiation [2,3]. In the lung, TTF-1 regulates the expression of
genes coding for the surfactant proteins Sftpa1, Sftpb, and Sftpc, and
clara cell secretory protein (CCSP). All these proteins are critical for
lung function as surface tension reducing, anti-inﬂammatory, and
immunomodulatory factors [1]. Suppression of TTF-1 translation in
a cultured lung explant model results in inhibition of branching
morphogenesis [4], while its deletion leads to extensive defects in
the ventral region of the forebrain [5] and non-viable pups with a
complete lack of lung parenchyma and thyroid tissue [5]. Beside theedicine, Floating Hospital for
St, Boston, MA 02111, USA.
(C.E.L. Dammann).
l rights reserved.effects in the developing lung, TTF-1 has a prominent role in epithelial
cell regeneration [6,7] and lung cancer [7]. In lung cancer biology,
TTF-1 seems to have a zwitter function, driving oncogenic aspects in
some [8–11] and a more favorable prognosis in other lung adenocar-
cinoma cases [12]. This is paralleled by the observation that ErbB4, a
member of the receptor tyrosine kinase family can be either oncogen-
ic or tumor suppressive [13,14]. Myosin Binding Protein H (MYBPH)
has recently been discovered as a TTF-1 downstream target in its in-
hibition of invasion and metastasis development [15]. The upstream
molecular mechanism that controls the expression of TTF-1 and its
transcriptional activity is still not fully understood.
ErbB4 is known for its involvement in differentiation processes in
the breast, the central nervous system, and the lung [16–21]. ErbB4,
similar to TTF-1, is critical for the progression of morphologic and
functional late fetal lung development [19,22]. ErbB4 deletion leads
to delayed fetal Sftpb expression [19] and alveolar simpliﬁcation
and a hyperreactive airway system in the adult lung [23]. Recently
it has been shown that neuregulin (NRG)-induced ErbB4 activation
leads to proteolytic cleavage [24,25] of the receptor and the 80 kDa
intracellular domain (4ICD) [26] translocates to the nucleus [27] to
interact with other nuclear receptors and transcription factors. In its
promoting effect on Sftpb expression, ErbB4 interacts with Estrogen
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and Activator of Transcription (Stat)5A [29]. There is limited informa-
tion on the regulation of TTF-1 gene expression by hormones, cyto-
kines and other biological agents [2,30]. Since both, ErbB4 and TTF-1
are critical in terminal fetal lung development and function we here
mechanistically analyze their interactions by hypothesizing that
ErbB4 is an upstream regulator of TTF-1.2. Materials and methods
The mouse lung epithelial cell line (MLE-12) was obtained from
American Type Culture Collection (Wesel, Germany); rabbit polyclon-
al TTF-1 (H-190), rabbit polyclonal ErbB4 (C-18) (suitable forWestern
Blot), and normal rabbit IgG were obtained from Santa Cruz Biotech-
nology (Heidelberg, Germany); mouse monoclonal c-ErbB4 antibody
(clone HFR-1) (suitable for immunoﬂuorescence) was from Thermo
Fisher Scientiﬁc GmbH (Dreieich, Germany); goat anti-rabbit IgG
(HRP-labeled, H + L), goat anti-mouse IgG (HRP-labeled, H + L),
and 10% non-immune goat serum were from Zymed Laboratories Inc.
(South San Francisco, CA); Alexa Fluor 488 goat anti-mouse IgG
(H + L) and Alexa Fluor 568 anti-rabbit IgG (H + L)were fromMolec-
ular Probes (Karlsruhe, Germany); rabbit polyclonal anti-sheep Sftpb
was from Chemicon Europe (Schwalbach/Ts, Germany); puriﬁed
mousemonoclonal anti-phosphotyrosine antibodywas from BD Biosci-
ences (Heidelberg, Germany); rabbit polyclonal anti-phosphoserine
antibodywas fromMillipore (Schwalbach/Ts, Germany);mousemono-
clonal anti-actin clone AC-40, 4,6-Diamidino-2-phenylindole, dilactate
(DAPI), and bovine serum albumin (BSA) were obtained from Sigma
(Hamburg, Germany); protein A Sepharose™ CL-4B, Western Blotting
Detection Reagents (enhanced chemiluminescence, ECL), and cDNA
Kit were from Amersham Biotechnologies (Munich, Germany);
Dulbecco's Modiﬁed Eagles Medium containing glutamine (DMEM)
was obtained from PAA-Laboratories (Coelbe, Germany). Fetal calf
serum was from PAN Biotech GmbH (Aidenbach, Germany); TaqMan
Universal PCR Master Mix and ABI PRISM™ Big Dye Terminator Cycle
Sequencing Ready Reaction Kit was from Applied Biosystems (Darm-
stadt, Germany); Total RNA Isolation Reagent (TRIR) was obtained
from ABgene (Darmstadt, Germany) and Plasmid Midi Kit from Qiagen
(Hilden, Germany). FuGene® HD Transfection Reagent was from Roche
Applied Science (Mannheim, Germany). The Dual-Glo Luciferase Assay
System was from Promega (Mannheim, Germany). The forward
primers (FP), reverse primers (RP) and probes for Actb, Sftpb and
TTF-1 were from Eurogentec (Cologne, Germany). Neuregulin 1β was
produced using an expression vector kindly provided by Kermit
Carraway III (UC Davis, CA) and puriﬁed by Dr. Ann Kane, Phoenix
Laboratory (Tufts Medical Center, Boston, MA). NRGwas diluted in glu-
tamine containing DMEM and used it in a ﬁnal concentration of 33 nM.2.1. Overall experimental approach
The ﬁrst aspect of our approach was focused on the individual
and combined effects of ErbB4 and TTF-1 on cell viability (Section
3.1), Sftpb mRNA and protein expression (Section 3.2) and promoter
activity (Section 3.3). This was followed by studies elucidating
the interactions of these two proteins by studying their cellular
colocalization (Section 3.4), and conﬁrming it in subcellular fraction-
ation (Section 3.5) and co-immunoprecipiation studies (Section 3.6).
Next we studied the effect of neuregulin on TTF1 expression (Section
3.7) and promoter activity (Section 3.8). In order to exclude endoge-
nous ErbB4 effects on this interaction we repeated the experiments
in primary fetal ErbB4-deleted type II cells. Finally we analyzed
whether ErbB4 cleavage and nuclear trafﬁcking were critical for
TTF-1-induced Sftpb regulation (Section 3.9) and TTF-1 expression
(Section 3.10).2.2. Plasmids
pEGFP N3 (control), pHER4 (full-length human ErbB4 receptor),
pHER4muNLS (human ErbB4 receptor with defective nuclear localiza-
tion signal), and Sftpb promoter luciferase reporter plasmid were
used as previously published [27,29,31]. HER4 refers to the human
ErbB4 receptor plasmid in the rest of the manuscript, pRC/CMV/
Nkx2.1 (TTF-1 expression plasmid) and TTF-1 promoter luciferase
reporter plasmid was kindly provided by Dr. Whitsett (Cincinnati
Children's Hospital Medical Center, Cincinnati, OH) [32].2.3. Transfection experiments
A mouse lung epithelial cell line (MLE-12) was used for most of
the transfection experiments. This cell line was established from pul-
monary tumors in a mouse transgenic for the SV40 large T antigen
under the control of the promoter region of the human Sftpc gene.
The cells secrete phospholipids in response to phorbol esters and
ATP, but not in response to forskolin [33]. MLE-12 cells are easily
transfectable and express Sftpb, TTF-1, and ErbB4. Also, their response
to NRG is comparable to fetal type II cells [22]. Transfection protocols
were used as previously published [29]. To examine the effects of
overexpression of ErbB4 and TTF-1 and to study its effect on Sftpb
promoter and TTF-1 promoter activity, MLE-12 cells were transfected
with a human ErbB4 construct [28], a TTF-1 construct, an empty En-
hanced Green Fluorescent Protein (EGFP) control construct, and a
Sftpb promoter luciferase reporter plasmid [28] or a TTF-1 promoter
luciferase reporter plasmid. The amount of DNA was adjusted as sug-
gested by the manufacturer and previously published [28,29] to keep
the amount of transfected DNA and transfection reagent similar in
each transfection experiment. To study the importance of the ErbB4
nuclear translocation, cells were transfected with an HER4 mutant,
defective in the nuclear localization signal (HER4muNLS) [28]. The
cells were transfected for 48 h using FuGene transfection reagent
as previously described [28] in accordance to the manufacturer
suggestions.2.4. MTT-assay
Cell viability was examined using a MTT-assay. In this colori-
metric assay the yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, a yellow tetrazole) is reduced to pur-
ple formazan in the mitochondria of living, metabolically active
cells. The amount of formazan is directly proportional to the cell num-
ber [34]. MLE-12 cells were grown in a 96-well plate at a concentra-
tion of 2.5 × 103 cells per well. After a 3-hour serum starvation,
cells were treated for 24 h with serum-free DMEM (controls) or
NRG (33 nM). After incubating with MTT-solution for 2 h at 37 °C,
the reaction was stopped by isopropanol-HCl. Media was removed
and 3% SDS and isopropanol-HCl were added. Absorption was mea-
sured at 570 nm.2.5. RNA isolation and cDNA synthesis
Cells were plated in 6 well plates until they reached 90% conﬂu-
ence. After being serum-starved for 3 h, cells were treated for 24 h
with serum-free DMEM (controls) or NRG (33 nM). Total RNA isola-
tion reagent was used for cell lysis. RNA was isolated by guanidinium
thiocyanate lysis followed by acid phenol/chloroform extraction [35].
After reversed transcription, 5 μg of total RNAwas used for cDNA syn-
thesis in a 15 μl reaction volume containing 1× DTT, 0.2 μg Hexamer
Primer, and 5× Bulk Mix for 1 h. The resulting cDNA was used for
real-time ampliﬁcation reactions.
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The cDNA levels of the Sftpb gene, the TTF-1 gene, and the Actb
gene were measured by real-time PCR. Actin was used as a reference
gene and internal control to normalize the target gene cDNA level for
Sftpb and TTF-1. The linearity of each RT-PCR reaction was conﬁrmed
by using serial dilutions of the DNA template (primer efﬁciency:
β-Actin 2.6, Sftpb 2.1, TTF-1 2.1). The 20 μl reaction mixture
contained 1 μl of the cDNA template, 10 μl TaqMan universal master
mix, 300 nM each of forward primer (FP) and reverse primer (RP),
and 200 nM probe (Table 1) [23]. An ABI PRISM 7900 sequence detec-
tion system was used for ampliﬁcation and detection of speciﬁc prod-
ucts. The initial denaturation and enzyme activation were done at
95 °C for 10 min, followed by 45 cycles at 95 °C for 15 s, and 60 °C
for 1 min. The threshold cycle (Ct) was determined for each gene.
For relative expression levels, ΔCt values were calculated as differ-
ences in the Ct values of the target gene and the reference gene. The
difference in the ΔCt values of the treated cells compared to the
control cells was calculated as ΔΔCt and presented inversely propor-
tional to the levels of Sftp or TTF-1 mRNA. For each assay, speciﬁcity
was conﬁrmed by sequencing the PCR products on both strands using
capillary electrophoresis with POP-6™-Polymer on anABI 3100Genetic
Analyzer (Applied Biosystems).
2.7. Co-immunoprecipitation and Western blotting
MLE-12 cells were serum-starved for 3 h and stimulated for 2 min
withNRG (33 nM), treated for 24 hwith NRG (33 nM) or left untreated
(controls). Cells were lysed in lyses buffer or co-immunoprecipitation
buffer as described before [28,36]. Lysates were cleared by micro-
centrifugation for 15 min at 4 °C. A Lowry protein assay was used to
determine total concentration of protein. For co-immunoprecipitation
300 μg of total protein was incubated for 90 min with the speciﬁc re-
ceptor antibody (anti-ErbB4 C-7, 1:10; anti-TTF-1 H-190, 1:50) at
4 °C. Protein-A-sepharose was added and incubation was continued
for another 90 min at 4 °C. The beads were collected by micro-
centrifugation at 14,000 rpm for 10 min, washed three times with
co-immunoprecipitation washing buffer and boiled in Laemmli buffer
for 5 min at 100 °C. The proteins were separated by 10% SDS polyacryl-
amide gel electrophoresis (resolving gel: 10% (v/v) acrylamide;
400 mM Tris–HCl pH 8.8; 0.1% (v/v) SDS; 0.07% (v/v) TEMED; 0.05%
(v/v) APS; stacking gel: 4% (v/v) acrylamide; 125 mM Tris–HCl
pH 6.8; 0.1% (v/v) SDS; 0.1% (v/v) TEMED; 0.05% (v/v) APS) and trans-
ferred to a nitrocellulose membrane. Blots were blocked in 1% BSA andTable 1
Primer sequences.
β-Actin
Forward primer
(FP):
5′-AGGTCATCACTATTGGCAACGA-3′
Reverse primer
(RP):
5′-CAACGTCACACTTCATGATGGA-3′
Probe: 5′(FAM)-AGCCTTCCTTCTTGGGTATGGAATCCTGT-(TAMRA)3′
Surfactant protein B (Sftpb)
Forward primer
(FP):
5′-ATGGCCAAGTCGCACCTACT-3′
Reverse primer
(RP):
5′-CCAGAATTGAGGGCCTTGTG-3′
Probe: 5′(FAM)-CCCAGGTGCAGCTATCACGTGG-(TAMRA)3′
TTF-1
Forward primer
(FP):
5′-CAC Acg ACT CCg TTC TCA gTg T-3′
Reverse primer
(RP):
5′-CATGCAGGCAAAGCAGTCA-3′
Probe: 5′-(FAM)-TgA CAT CTT gAg TCC CCT g-(TAMRA)3′incubated with antibodies against individual proteins (puriﬁed mouse
anti-phosphotyrosine antibody, 1:1000; anti-TTF-1 H-190, 1:750;
anti-ErbB4 C-18, 1:750; anti-Sftpb, 1:750; or anti-β-Actb, 1:15,000)
overnight at 4 °C. Secondary antibody (HRP-labeled goat anti-mouse
IgG, 1:5000; or goat anti-rabbit IgG, 1:10,000) was applied and the
proteinswere visualized by enhanced chemiluminescence (ECL). Mem-
branes were stripped in strip buffer for 30 min at 50 °C, up to three
times. An immunoprecipitation with a control rabbit IgG antibody was
performed and probed with ErbB4 and TTF-1 antibody to control for
the ErbB4 and TTF-1 antibody speciﬁcity.
2.8. Luciferase reporter gene assay
Cells were transfected with the Sftpb promoter luciferase reporter
plasmid or the TTF-1 promoter luciferase reporter plasmid and the
renilla luciferase control vector (pRL-TK) alone or together with the dif-
ferent plasmids as described above. 48 h after transfection, cells were
starved for 3 h and treated with DMEM (control) or NRG (33 nM) for
24 h. Luciferase assaywas done using the Dual-Glo Luciferase assay sys-
tem. Brieﬂy, luciferase reagentwas added to cells in growthmedia. After
10 min incubation theﬁreﬂy luminescencewasmeasured. Stop andGlo
reagentwas added to the cells and renilla luciferasewasmeasured after
a 10-min incubation. The ratio of luminescence from the experimental
reporter to the luminescence from the control reporter was calculated
and normalized to a control well.
2.9. Confocal microscopy
MLE-12 cells were grown on glass cover slips in 24-well plates.
After a 3-hour serum starvation, cells were treated with serum-free
DMEM (controls) or stimulated for 2 min or treated for 24 h with
NRG (33 nM). Cells were washed with PBS, ﬁxed for 20 min in 3%
paraformaldehyde, rinsed again with PBS, permeabilized in 0.5%
TritonX-100/ PBS for 5 min and blocked for 1 h with 10% normal
goat serum. After a 30-minline incubation with the primary antibody
(ErbB4 clone HFR-1, 1:25; TTF-1 H-190, 1:50), cells were washed
with PBS and incubated with a secondary antibody (Alexa Fluor
488, 1:100; Alexa Fluor 568, 1:200) for another 30 min. After staining
with DAPI (1:100,000) for 10 min, cells were mounted onto glass
slides and examined using a Leica Inverted-2 DM IRB confocal laser
scanning microscope connected to a TCS SP2 AOBS scanhead (Leica,
Wetzlar, Germany).
2.10. Subcellular fractionation
MLE-12 cells were serum-starved for 3 h and stimulated for 2 min
or treated for 24 h with NRG (33 nM). Cells were scraped in PBS and
the pellet was resuspended in Nuclei Buffer (pH 7.9, 10 mM Hepes,
1.5 mM MgCl2, 10 mM KCl, 1% Triton X-100, 0.5 mM DTT). After a
10-min incubation on ice, cells were centrifuged for 10 min at
10,000 g, 4 °C. The supernatant (cytoplasmic fraction) was stored at
−80 °C and the pellet was resuspended in high salt buffer (pH 7.9,
10 mM Hepes, 400 mM NaCl, 0.1 mM EDTA, 5% glycerol, and 0.5 mM
DTT) and kept on ice for 20 min. The nuclei fraction was cleared by
microcentrifugation for 10 min at 10,000 g, 4 °C. The supernatant
(nuclear fraction) was stored at −80 °C until further processed. Pro-
teins were separated on a 10% SDS polyacrylamide gel and further
processed as described in the co-immunoprecipitation section.
2.11. Preparation of primary fetal mouse ErbB4-deleted type II epithelial
cell cultures
Primary type II cells were freshly isolated from time-dated preg-
nant transgenic ErbB4 HER4heart(−/−) mice as previously described
[29]. These mice have been rescued from their lethal cardiac defects
by expressing a human ErbB4 (HER4heart) cDNA under the cardiac-
Fig. 1. Co-expression of HER4 and TTF-1 decreases lung epithelial cell viability under
control and NRG treatment conditions. Lung epithelial cell viability was measured in
MLE-12 cells, transfected with full-length ErbB4 (HER4), TTF-1 or HER4, and TTF-1
(HER4/TTF-1) under control conditions (black bars) and after 24 h NRG treatment
(gray bars). Results were compared to EGFP-transfected control cells (A) or
NRG-treated EGFP-transfected cells (B). *P ≤ 0.01, **P ≤ 0.001, n = 10–11.
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culties of the transgenic mice and a lower transfection efﬁciency
seen in primary fetal type II cells, especially in the experiments
where two or three plasmids were used, only experiments focusing
on ErbB4 effects on endogenous TTF-1 expression were performed
in primary fetal type II cells with an ErbB4 negative background.
This eliminated the interference of the plasmid-derived from the
endogenous-expressed ErbB4, present in all MLE-12 experiments.
The animal research protocol was approved by the institutional
IACUC at Hannover Medical School. Pregnant HER4heart(−/−) mice
were sacriﬁced at E17.5 of gestation by CO2 inhalation. The CO2 effect
on the fetal lung cells is minimal because the exposure time used for
euthanasia of the maternal mice is very short [19,29,38,39]. Fetal
lungs were removed, washed in sterile Hank's buffered salt solution,
minced with a razorblade, and incubated with Collagenase Type II
(Worthington Biochemical Corp., Lakewood, NJ) for 2 h at 37 °C.
The reaction was stopped on ice for 30 min and the tissue was centri-
fuged, the pellet resuspended in DMEM, and incubated for another
30 min on ice. After a second centrifugation the pellet was re-
suspended in DNase and trypsin and incubated for 12 min at 37 °C.
The reaction was stopped by DMEM containing 10% fetal calf serum
(FCS). The cells were ﬁltered, centrifuged, resuspended in DMEM
containing 10% FCS, and plated in culture dishes for 60 min at 37 °C
(21% 02/5% C02) to allow for differential adherence of lung ﬁbroblasts.
For type II cell isolation the supernatant from the ﬁrst differential
adherence was centrifuged, the cell pellet resuspended in DMEM
containing 10% FCS, and plated in culture ﬂasks for 60 min at 37 °C
for a second differential adherence. Supernatants were removed and
centrifuged. Cell pellets were resuspended and plated in DMEM
containing 20% FCS and grown until further use.
2.12. Data analysis
All values were presented as mean ± SEM and the values of the
treated groups were presented as relative values normalized for the
experimental speciﬁc control group unless otherwise stated. The
effects of TTF-1 and ErbB4 overexpression on cell viability, TTF-1
and Sftpb expression, and TTF-1 and Sftpb promoter activity were
expressed as percentages of controls transfected with EGFP. The effect
of NRG was expressed as percentage of EGFP-transfected cells treated
with NRG. The effects of the human ErbB4 mutant (HER4muNLS) on
TTF-1 and Sftp expression, and TTF-1 and Sftpb promoter activity
were expressed as percentages of HER4-transfected cells. To evaluate
the results for their statistical signiﬁcance a two-way ANOVA was
used. A post hoc Bonferroni correction for multiple comparisons
was used when appropriate. Values of P b 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. Co-expression of HER4 and TTF-1 decreases lung epithelial cell
viability under control and NRG treatment conditions
To study the effect of plasmid-derived ErbB4 and TTF-1 on lung
epithelial cell viability, untreated and NRG-treated MLE-12 cells
were transfected with full-length human ErbB4 (HER4), TTF-1, or a
combination of HER4 and TTF-1 (HER4/TTF-1). NRG treatment had
no effect on cell viability in EGFP-transfected control cells (105 ±
10%, n = 11, P N 0.05). Overexpression of HER4 (100 ± 6%, n = 11,
P N 0.05) and TTF-1 (97 ± 5%, n = 11, P N 0.05) had also no effect,
whereas co-expression of HER4 and TTF-1 signiﬁcantly decreased
lung epithelial cell viability to 83 ± 4% (n = 11, P b 0.05). All results
were compared to untreated (100 ± 3%, n = 11) cells transfected
with an EGFP control plasmid (Fig. 1A). 24 h of NRG treatment did
not change cell viability in HER4- (103 ± 5%, n = 10, P N 0.05) or
TTF-1- (101 ± 5%, n = 10, P N 0.05) overexpressing cells. NRG didnot change the inhibitory effect on cell viability induced by HER4/
TTF-1 overexpression (75 ± 4%, n = 10, P b 0.001). NRG treatment
results were compared to NRG-treated cells transfected, with an
EGFP control plasmid (100 ± 2%, n = 10) (Fig. 1B).
3.2. Co-expression of HER4 and TTF-1 stimulates Sftpb mRNA and protein
expression under control and NRG treatment conditions
To examine whether plasmid-derived ErbB4 and TTF-1 over-
expression had an effect on Sftpb mRNA (Fig. 2A, B) and protein ex-
pression (Fig. 2C, D), untreated and NRG-treated MLE-12 cells were
transfected with HER4, TTF-1, or a combination of HER4 and TTF-1
(HER4/TTF-1). NRG treatment had a stimulatory effect on Sftpb
mRNA expression in EGFP-transfected control cells (0.4 ± 0.2, n =
15, P b 0.05). Overexpression of human ErbB4 (HER4) signiﬁcantly
increased Sftpb mRNA expression (0.5 ± 0.1, n = 10, P b 0.01)
whereas the overexpression of TTF-1 alone had no effect (0.08 ±
0.2, n = 11, P N 0.05). The co-expression of both proteins stimulated
Sftpb mRNA expression (0.8 ± 0.3, n = 9, P b 0.01). Results were
compared to untreated cells transfected with an EGFP control con-
struct (Fig. 2A). NRG treatment did not change the effect of the previ-
ously mentioned overexpression on Sftpb mRNA expression, keeping
the increase in HER4 (0.4 ± 0.1, n = 8, P b 0.05) and HER$/TTF-1-
(1.1 ± 0.2, n = 8, P b 0.01) overexpressing cells and did not effect
it in TTF-1- overexpressing cells (0.1 ± 0.2 n = 9, P N 0.05) when
compared to NRG-treated cells transfected with an EGFP control
construct (Fig. 2B).
NRG treatment had no additional effect on Sftpb protein expres-
sion in EGFP-transfected cells (89 ± 4%, n = 13, P N 0.05). HER4
overexpression did not change Sftpb protein expression (94 ± 6%,
n = 13, P N 0.05), whereas TTF-1 overexpression led to a trend to-
wards an increase (120 ± 9%, n = 13, P N 0.05) and the combined
expression of HER4 and TTF-1 (185 ± 36%, n = 13, P b 0.001)
Fig. 2. Co-expression of ErbB4 and TTF-1 stimulates SftpbmRNA, protein expression and promoter activity under control and NRG treatment conditions. MLE-12 cells were transfected
with HER4, TTF-1 or HER4/TTF-1. Sftpb mRNA (A, B) and protein (C, D) expression was measured under control conditions (black bar) and after 24 h treatment with NRG (gray bars).
Results were compared to EGFP-transfected control cells (A, C) or NRG-treated EGFP-transfected cells (B, D). Representative Western Blots are shown on the upper part of Fig. 2C and
D. Sftpb promoter activity was measured in MLE-12 cells transfected with full-length ErbB4 (HER4), TTF-1 or HER4/TTF-1 under control conditions (black bars) and after NRG treatment
(gray bars). Results were compared to EGFP-transfected control cells (E) or NRG-treated EGFP-transfected cells (F). *P ≤ 0.01, **P ≤ 0.001, n = 8–21.
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to cells transfected with the EGFP control construct (100 ± 2%, n =
13) (Fig. 2C). NRG treatment did not change the Sftpb protein expres-
sion in HER4 overexpressing cells (117 ± 6%, n = 13, P N 0.05), but
led to a trend towards an increase to 130 ± 5% (n = 11, P N 0.05) in
TTF-1 overexpressing cells. The signiﬁcant increase in Sftpb protein
expression to 213 ± 28% (n = 13, P b 0.001) in NRG-treated HER4/
TTF-1 overexpressing cells was not statistically different from non NRG-
treated transfected cells. Results were compared to EGFP-transfected
cells treated with NRG (100 ± 2%, n = 13) (Fig. 2D).
3.3. Co-expression of HER4 and TTF-1 induces Sftpb promoter activity
under control and NRG treatment conditions
To determine if plasmid-derived ErbB4 and/or TFF-1 expression
stimulate Sftpb promoter activity, untreated and NRG-treated
MLE-12 cells were transfectedwith a Sftpb promoter luciferase report-
er plasmid. NRG treatment had no effect on luciferase activity in
EGFP-transfected cells (103 ± 8%, n = 20, P N 0.05). Co-transfection
of the Sftpb promoter luciferase reporter with full-length human
ErbB4 (HER4) or TTF-1 showed a trend towards an increased lucifer-
ase activity in untreated cells (121 ± 16%, n = 18, P N 0.05; 147 ±
17%, n = 18, P N 0.05, respectively). A combined expression of HER4
and TTF-1 showed a signiﬁcant increase in luciferase activity to
283 ± 35% (n = 17, P b 0.01) when compared to EGFP-transfecteduntreated cells (100 ± 3%, n = 21) (Fig. 2E). NRG did not change
these responses in HER4- and in TTF-1-transfected cells (101 ± 16%,
n = 17, P N 0.05; 149 ± 31%, n = 17, P N 0.05, respectively). The
combined expression of HER4 and TTF-1 led to a signiﬁcant increase
in luciferase activity to 299 ± 35% (n = 19, P b 0.001) in NRG-
treated cells, which was similar to the response in nonNRG-treated
transfected cells. Results were compared to EGFP-transfected,
NRG-treated cells (100 ± 4%, n = 20) (Fig. 2F).
3.4. NRG induces nuclear translocation of ErbB4 in MLE12 cells
Endogenous TTF-1 localized to the nucleus while endogenous
ErbB4 localized to the cell membrane and the cytoplasm in untreated
cells only. Short NRG stimulation led to a more pronounced
perinuclear and nuclear staining, leading to co-localization of ErbB4
and TTF-1 in this region. This was further enhanced in cells treated
for 24 h with NRG. DAPI staining conﬁrmed nuclear localization of
these proteins (Fig. 3).
3.5. NRG induces ErbB4 cleavage and enrichment of 4ICD in the nuclear
fraction
Subcellular fractionation studies isolating the cytoplasmic and nu-
clear compartments of the cell conﬁrmed the localization of endoge-
nous ErbB4 and endogenous TTF-1 in NRG-stimulated (2 min) and
Fig. 2 (continued).
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(42 kDa) and LAP2 (53 kDa) antibody probing was used to conﬁrm
the purity of the cytoplasmic and nuclear fraction, respectively
[40,41]. The full-length ErbB4 receptor (195 kDa) was found in the
cytoplasmic fraction and in the nuclear fraction in control cells and
to a small extent in the nuclear fraction after a 24-hour NRG treat-
ment. Two minutes of NRG stimulation and more pronounced a
24-hour treatment with NRG led to enrichment of ErbB4's 80 kDa in-
tracellular domain 4ICD in the nucleus. The transcription factor TTF-1
localized to the nucleus independent of NRG treatment (Fig. 4).
3.6. ErbB4 and TTF-1 co-precipitate each other
We further conﬁrmed the interaction of endogenous ErbB4 and
endogenous TTF-1 by co-immunoprecipitation analyses of both pro-
teins. Both co-precipitated each other under all conditions tested.
NRG stimulation induced tyrosine phosphorylation of ErbB4 and
serine phosporylation of TTF-1, indicating the tight interactions of
these two proteins (Fig. 5A and B). Immunoprecipitations with a
control IgG antibody did not show any nonspeciﬁc antibody binding
(Fig. 5C).
3.7. NRG stimulates TTF-1 mRNA and protein expression in HER4-
expressing cells
NRGsigniﬁcantly induced TTF-1mRNAexpression in EGFP-transfected
control MLE-12 cells (0.4 ± 0.2, n = 15, P b 0.05). Plasmid-derived
HER4 expression showed a trend towards an increase in its expression
(0.5 ± 0.2, n = 10, P N 0.05), but did not reach statistical signiﬁcancecompared to EGFP-transfected control cells. NRG treatment signiﬁcantly
increased TTF-1 mRNA expression in HER4-overexpressing cells (1.6 ±
0.4, n = 9, P b 0.01) compared to NRG-treated EGFP-expressing control
cells (Fig. 6A).
NRG treatment did not changed TTF-1 protein expression (98 ±
5%, n = 19, P N 0.05) in EGFP-transfected control cells, whereas
HER4 overexpression signiﬁcantly increased the TTF-1 expression to
117 ± 7% (n = 10, P b 0.01), when compared to untreated cells
transfected with an EGFP control construct (100 ± 2%, n = 19)
(Fig. 6B). NRG treatment signiﬁcantly increased TTF-1 protein expres-
sion in HER4-overexpressing cells (135 ± 9%, n = 10, P b 0.001),
when compared to NRG-treated cells transfected with an EGFP con-
trol construct (100 ± 3%, n = 19), but this increase was not different
from the response in nonNRG-treated transfected cells (Fig. 6C).
To separate the plasmid-derived from the endogenous ErbB4
effects, we conﬁrmed the effect of NRG stimulation and ErbB4 pres-
ence on TTF-1mRNA expression in primary ErbB4-deleted fetal mouse
type II cells. Fetal cells were freshly isolated from HER4heart(−/−) lungs
transfected with a full-length ErbB4 or a GFP control vector and treated
withNRG. NRG treatment showed a trend towards a decrease in endog-
enous TTF-1mRNA expression in ErbB4-deleted EGFP-transfected con-
trol cells (−1.2 ± 0.4, n = 4, P N 0.05), whereas re-expression of the
human ErbB4 (HER4) showed a trend towards an increase in TTF-1
mRNA expression in untreated cells (0.7 ± 0.3, n = 5, P N 0.05), com-
pared to cells transfected with an EGFP control construct. NRG treat-
ment signiﬁcantly stimulated the TTF-1 mRNA expression in HER4
re-expressing primary type II cells (1.3 ± 0.1, n = 3, P b 0.01) when
compared to NRG-treated type II cells transfected with an EGFP control
construct (Fig. 6D).
Fig. 3. NRG induces nuclear translocation of ErbB4 in MLE-12 cells. MLE-12 cells were stimulated with NRG for 2 min or treated for 24 h. Confocal microscopy was used to study the
cellular localization of ErbB4 (green dye) and TTF-1 (red dye) and the co-localization of bo
Fig. 4. NRG induces ErbB4 cleavage and enrichment of 4ICD in the nuclear fraction. Cell
fractionation was done in MLE-12 cells under control conditions (C) and after 2 min
(NRG 2 min) or 24 h (NRG 24 h) NRG treatment. Blots showing the cytoplasmic and
the nuclear fraction were probed with ErbB4, TTF-1, LAP2, and β-Actin (Actb) antibodies.
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To determine if the expression of plasmid-derived HER4 stimulates
the TTF-1 promoter activity, untreated and NRG-treated MLE-12 cells
were transfected with a TTF-1 promoter luciferase reporter plasmid.
NRG treatment had no signiﬁcant effect on TTF-1 promoter luciferase
activity (126 ± 20%, n = 8, P N 0.05) in EGFP-transfected cells, while
transfection with full-length human ErbB4 (HER4) increased luciferase
activity in untreated cells (234 ± 59%, n = 7, P b 0.01) when com-
pared to untreated (100 ± 6%, n = 8) cells transfected with the EGFP
control construct (Fig. 6E). In NRG-treated HER4-overexpressing cells
the luciferase activity was increase (275 ± 68%, n = 6, P b 0.001),
when compared to NRG-treated control cells transfected with EGFP
(100 ± 4%, n = 8) (Fig. 6F). This increase was not different from the
response in nonNRG-treated transfected cells.
3.9. Nuclear translocation of HER4 is required for the ErbB4/TTF-1-induced
Sftpb expression
To examine whether the ErbB4 nuclear translocation is required for
ErbB4 effects on Sftpb mRNA (Fig. 7A), protein expression (Fig. 7B), or
th proteins (overlay). DAPI (blue dye) was used to conﬁrm nuclear staining.
Fig. 5. ErbB4 and TTF-1 co-immunoprecipitate each other. TTF-1 co-immunoprecipitation (Co-IP) (A) and ErbB4 Co-IP (B) were done in MLE-12 cells under control conditions and
after 2 min (NRG 2 min) or 24 h (NRG 24 h) NRG treatment. An IgG IP (C) was done to conﬁrm antibody speciﬁcity. Blots were probed with anti-phosphotyrosine (α-P-tyr),
anti-phosphoserine (α-P-ser), anti-ErbB4, and anti-TTF-1 antibody as stated on the right side next to the blots.
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cells were transfected with a plasmid-derived HER4 construct, which
has a mutated nuclear localization sequence (HER4muNLS). Prevention
of HER4 nuclear entry prevented the ErbB4-induced increase of Sftpb
mRNA expression (−0.7 ± 0.2, n = 8, P b 0.01). Neither NRG treat-
ment (−0.5 ± 0.1, n = 8, P b 0.01, respectively) nor additional TTF-1
overexpression in untreated and NRG-treated cells did rescue or
overcome this inhibition (−0.8 ± 0.2, n = 9, P b 0.01;−0.7 ± 0.2,
n = 6, P b 0.05, respectively) (Fig. 7A). All results were compared to
untreated or NRG-treated cells transfected with the full-length ErbB4
receptor construct (HER4) or to untreated or NRG-treated HER4/
TTF-1-transfected cells, respectively.
In contrast to the effect on gene expression, expression of a
plasmid-derived HER4muNLS mutant resulted in minimal change of
Sftpb protein expression towards a decrease in untreated (89 ±10%,
n = 7, P N 0.05) and in NRG-treated cells (81 ± 10%, n = 7,
P N 0.05) compared to untreated or NRG-treated HER4-transfected
cells (100%, n = 7; 100%, n = 7, respectively). Additional TTF-1 ex-
pression somewhat potentiated the decrease in Sftpb protein expres-
sion making it statistical signiﬁcant in untreated (58 ± 7%, n = 7,
P b 0.001) and NRG-treated cells (59 ± 8%, n = 7, P b 0.01). This
underlines the importance of ErbB4 nuclear translocation in ErbB4/
TTF-1 signaling on Sftpb expression. The values were compared to
untreated or NRG-treated HER4/TTF-1-transfected cells (100%, n =
7; 100, n = 7, respectively) (Fig. 7B).
The inability of HER4 to translocate to the nucleus when expressing
plasmid-derived HER4muNLS, decreased Sftpb promoter activity signif-
icantly to 78 ± 9% (n = 7, P b 0.01) in untreated cells. NRG treatment
did not rescue this inhibition (64 ± 13%, n = 5, P b 0.01). Resultswere
compared to untreated (100 ± 2%, n = 7) or NRG-treated (100 ± 6%,
n = 7) HER4-transfected cells. Additional overexpression of TTF-1 did
not signiﬁcantly change this inhibitory effect, leading to a decrease
in Sftpb promoter activity in untreated (58 ± 6% n = 7, P b 0.0001)
and NRG-treated cells (56 ± 9%, n = 6, P b 0.01). Transfected cellswere compared to untreated (100 ± 5%, n = 7) or NRG-treated
(100 ± 7%, n = 7) HER4/TTF-1-transfected cells (Fig. 7C).
3.10. Nuclear translocation of HER4 is required for TTF-1 expression
To study the effect of ErbB4 nuclear translocation on TTF-1 mRNA
(Fig. 8A), protein expression (Fig. 8B), and TTF-1 promoter activity
(Fig. 8C), untreated and NRG-treated MLE-12 cells were transfected
with plasmid-derived HER4muNLS. Inability of HER4 to localize to the
nucleus inhibited TTF-1 mRNA expression in untreated cells (−0.8 ±
0.3, n = 8, P b 0.05). NRG treatment did not overcome this inhibitory
effect (−0.9 ± 0.3., n = 10, P b 0.01). Results were compared to
untreated or NRG-treated cells transfected with the full-length human
ErbB4 (HER4) construct (Fig. 8A; compared to the results in Fig. 6A).
Inability of HER4 to translocate to the nucleus did not change TTF-1
protein expression when compared to HER4-transfected cells (81 ±
12%, n = 7, P N 0.05), but signiﬁcantly inhibited NRG-induced upreg-
ulation of TTF-1 in HER4-transfected cells (76 ± 8%, n = 7, P b 0.05).
All effects were compared to untreated or NRG-treated cells transfected
with the full-length HER4 construct (100, n = 7; 100, n = 7, respec-
tively) (Fig. 8B; compared to the results in Fig. 6B and C).
Expression of plasmid-derived HER4 mutant also inhibited TTF-1
luciferase activity to 43 ± 10% (n = 8, P b 0.0001) in untreated and
to 38 ± 10% (n = 8, P b 0.001) in NRG-treated cells, showing that
there is no additional effect added by NRG treatment. All results
were compared to untreated (100 ± 5%, n = 8) or NRG-treated
cells (100 ± 8%, n = 9) transfected with full-length HER4 (Fig. 8C;
compared to the results in Fig. 6E and F).
4. Discussion
Transcription factors play a central role in regulating the expression
of tissue-speciﬁc genes to control the function, homeostasis, and differ-
entiation of these tissues. TTF-1 is an important transcriptional regulator
Fig. 6. NRG stimulates TTF-1 mRNA, protein expression, and promoter activity in ErbB4-overexpressing cells. TTF-1 mRNA (A) and protein (B, C) expression was measured in
MLE-12 cells transfected with HER4 under control conditions (black bar) and after 24 h of treatment with NRG (gray bars). Results were compared to EGFP-transfected control
cells or NRG-treated EGFP-transfected cells. Representative Western Blots are shown above the densitometric graphs (B, C). Fetal HER4heart(−/−) type II epithelial cells were
transfected with HER4. TTF-1 mRNA expression was measured under control conditions (black bars) and after 24 h of treatment with NRG (gray bars). Results were compared
to EGFP-transfected control cells or NRG-treated EGFP-transfected cells (D). TTF-1 promoter activity was measured in MLE-12 cells transfected with a control plasmid (EGFP) or
full-length ErbB4 (HER4 under control conditions (black bars) and after NRG treatment (gray bars). Results were compared to EGFP-transfected control cells (E) or NRG-treated
EGFP-transfected cells (F). *P ≤ 0.01, **P ≤ 0.001, n = 9–19.
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lung development is illustrated by studies of TTF-1 null mice that
lack lung parenchyma [5]. TTF-1 regulates Sftpb promoter activity
[42] and its deﬁciency results in an inhibition of branching morpho-
genesis [4] and early postnatal death [43]. In the lung, it has been
shown that poly(ADP-ribose) polymerases (PARP-2 and PARP-1) en-
hance TTF-1-mediated activation of the Sftpb gene [44], but there is
limited information on the regulation of TTF-1 gene expression by
hormones, cytokines, and other biological agents like growth factors[2]. Here we present data for ErbB4 being a potential upstream regu-
lator of TTF-1.
Co-expression of human ErbB4 and TTF-1 results in a decrease
in lung epithelial cell proliferation. ErbB4 is known to be mostly in-
volved in differentiation processes, and not primary in cell prolifera-
tion like other ErbB receptors [45]. This result is in alignment with
the known function of TTF-1 being essential for the morphogenesis
and differentiation of the thyroid, the lung, and ventral forebrain
[2]. This effect of TTF-1 may relate to the mechanisms in developing
Fig. 7. Nuclear translocation of ErbB4 is required for the ErbB4/TTF-1-induced Sftpb expression. MLE-12 cells were transfected with HER4, HER4/TTF-1, HER4muNLS, or
HER4muNLS/TTF-1. Sftpb mRNA (A), protein (B) expression and Sftpb promoter activity (C) was measured under control conditions (black bars) and after 24 h treatment with
NRG (gray bars). Results were compared to untreated or NRG-treated cells transfected with HER4 or HER4/TTF-1. *P ≤ 0.01 **P ≤ 0.001, n = 5–9. Representative Western Blot
is shown above the results of the densitometric readings (B).
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reciprocally linked [46].
Surfactant synthesis is a crucial component of fetal lung develop-
ment in preparation for birth [47]. Deﬁciency of pulmonary surfac-
tants causes respiratory distress syndrome (RDS) among preterm
infants [48]. The growth factor neuregulin (NRG) is required for the
initiation of fetal surfactant synthesis [22]. Down-regulation of
ErbB4, the signaling receptor for NRG, leads to inhibition of surfactant
synthesis in primary fetal rat type II epithelial cells in vitro [36], while
in vivo ErbB4 deletion leads to a clinical phenotype of a hyperreactive
airway system and a histologic phenotype of alveolar simpliﬁcation,
chronic inﬂammation, and signiﬁcant Sftpd downregulation in the
postnatal lung [23]. While it would be very interesting to study the
interactions of ErbB4 and Sftpd in the adult lung, we here focused
on Sftpb, ErbB4, and TTF-1 interactions in the developing fetal lung,
since fetal ErbB4 deletion results in delayed fetal lung development,
especially delayed expression of Sftpb [19]. Also, Sftpb is the most
critical surfactant protein in reducing surface tension in the develop-
ing lung [49–51]. NRG stimulates Sftpb expression by initiation of
ErbB4 activation and ErbB4 processing, resulting in its chaperone
function for transcription factors like Stat5A [29]. Here we expand
on ErbB4 signaling clues, showing that ErbB4 functions as an up-
stream regulator of TTF-1, one of the most critical transcription fac-
tors in lung development and disease [2]. We speculate that in
addition to a TTF-1 upregulation through ErbB4, both proteins form
a functionally important complex to upregulate Sftpb expression by
directly binding to the promoter region of this gene. The region of
the Sftpb promoter spanning from bp−111 to−73 is a known com-
plex binding site for TTF-1 [49,52]. An upstream enhancer located inthe 5′-ﬂanking region of the human Sftpb gene (−439 to −331
base pair) has been found to bind to TTF-1 [53].
We here conﬁrmed that NRG stimulates the interactions of ErbB4
and TTF-1 and that NRG-induced cleavage of ErbB4 results in a trans-
location of 4ICD to the nucleus, previously published for other cell
types [13,24], seemed to be a critical process for Sftpb expression.
We have previously described that NRG is able to induce 4ICD to func-
tion as a nuclear shuttle for the transcription factor Stat5A. This func-
tion requires the presence of the nuclear localization sequence (NLS)
of 4ICD [29], while estrogen is able to induce nuclear localization of
4ICD independent of this NLS [28]. This suggests that the estrogen re-
ceptor might function as an independent nuclear shuttle mechanism
for 4ICD [28]. Here we show that NRG-induced nuclear interactions
of ErbB4 and TTF-1 also require 4ICD NLS for its effect on Sftpb ex-
pression (Fig. 9). Most of the nuclear processes regulated by 4ICD
are still unknown. The interactions of these proteins were conﬁrmed
by the fact that ErbB4 and TTF-1 co-precipitate each other. Despite
the fact that these interactions are baseline interactions and indepen-
dent of NRG treatment, NRG stimulates tyrosine phosphorylation of
ErbB4 and serine phosphorylation of TTF-1. This underlines the po-
tential impact of the strong interactions of those two signaling
pathways.
Phosphorylation of TTF-1 is required for tissue-speciﬁc gene regu-
lation [1]. Here we show that NRG-induced TTF-1 phosphorylation in-
duces Sftpb gene expression in lung epithelial cells. NRG also
stimulates TTF-1 mRNA and protein expression more potently in
lung epithelial cells which overexpress ErbB4, suggesting that ErbB4
receptor is synergistically enhancing NRG effects on TTF-1 expression.
This observation was conﬁrmed by experiments in primary fetal type
Fig. 8. Nuclear translocation of ErbB4 is required for TTF-1 expression. MLE-12 cells were transfected with HER4, or HER4muNLS. TTF-1 mRNA (A), protein (B) expression, and TTF-1
promoter activity (C) was measured under control conditions (black bars) and after 24 h of treatment with NRG (gray bars). Results were compared to untreated or NRG-treated
cells transfected with HER4. *P ≤ 0.01 **P ≤ 0.001, n = 7–10. Representative Western Blots are shown above the results of the densitometric readings (B).
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ErbB4, emphasizing that TTF-1 expression requires the expression of
full-length ErbB4.
There is some evidence that Hoxb3 is a transcriptional regulator
of the TTF-1 gene in early embryogenesis [54] and that TTF-1mRNA ac-
cumulation can be regulated by a posttranscriptional, Ras-sensitive
mechanism [55]. Our studies demonstrated that ErbB4 leads to TTF-1
promoter activation, suggesting in its upstream regulatory control.
Since nuclear translocation of ErbB4 is required for TTF-1 effects on
Sftpb expression, it might be speculated that ErbB4 cleavage-
induced signaling is most prominent in its effect on TTF-1 transcrip-
tional control. This is in alignment with known regulatory effects of
ErbB4 cleavage and 4ICD nuclear translocation on other transcription
factors in other organ systems [18,29,56]. It remains questionable if
ErbB4 directly or indirectly interacts with the TTF-1 promoter. There
might be other transcription factors involved, which form a complex
with TTF-1 and ErbB4. Since ErbB receptors lack any known structural
signatures required for DNA association [57], it is most likely that
ErbB4 does not directly interact with genomic DNA, but functions as
a transcriptional co-regulator.
In addition to the known function of TTF-1 [8–11] and ErbB4
[13,14] in lung cancer biology, mutations in TTF-1 and ErbB receptors
as well as their interactions can also lead to lung disease. For example,
EGFR mutations were signiﬁcantly more common in tumors express-
ing TTF-1 [58]. TTF-1 haploinsufﬁciency is a rare cause of neonatal or
infantile respiratory failure, often associated with congenital hypo-
thyroidism and neurologic symptoms recognized as the brain–lung–
thyroid syndrome [59].In summary, ErbB4 regulates TTF-1 expression and the interac-
tions of both proteins stimulate Sftpb expression in type II epithelial
cells. NRG induces the co-localization of ErbB4 and TTF-1 and inten-
siﬁes the stimulatory effect of ErbB4 on TTF1 expression, but does
not add additional effects on Sftpb expression and Sftpb promoter ac-
tivity. NRG also does not overcome the inhibitory effects when ErbB4
cleavage and nuclear translocation are prevented. Viewing our data in
the light of known involvements of TTF-1, Sftpb, and ErbB receptors
in lung disease, our results impact the knowledge of type II cell devel-
opmental biology to create potential approaches to prevent cell inju-
ry. Since this is an in vitro approach, further in vivo studies are needed,
where manipulating ErbB4 signaling can prove its positive enhance-
ment of TTF-1 effects on the fetal surfactant system and its usefulness
in the prevention or treatment of lung disease.
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Fig. 9. Schematic model of ErbB4 signaling in type II epithelial cells proposed by the authors. Neuregulin (NRG)-binding leads to activation and proteolytic cleavage of the phos-
phorylated (P) ErbB4 receptor [24,25]. The remaining membrane bound part (m80) is further processed by γ-secretase. The resulting 80 kDa ErbB4 intracellular domain (4ICD)
translocates to the nucleus [26] and enters via its nuclear localization sequence (NLS) [13,24] or NLS independently using an estrogen (E) activated estrogen receptor β (ERβ)
as a nuclear shuttle [28]. In our proposed model, 4ICD leads to TTF-1 promoter activation by binding via an additional transcription factor (TF) or linker to the promoter. This
newly formed complex binds and activates the Sftpb promoter to stimulate Sftpb expression.
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